These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26220355)

  • 1. Tumour response, correlates of survival and clinical benefit.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):433. PubMed ID: 26220355
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of cancer drugs on survival: often poorly evaluated.
    Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
    Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
    Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
    Zhuang SH; Xiu L; Elsayed YA
    Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 7. Dodging a dogma: is treating beyond progression beneficial?
    Naing A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive thoughts about progressive disease.
    Shah NP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748
    [No Abstract]   [Full Text] [Related]  

  • 9. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.
    Driscoll JJ; Rixe O
    Cancer J; 2009; 15(5):401-5. PubMed ID: 19826360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable disease is a valid end point in clinical trials.
    Tolcher AW
    Cancer J; 2009; 15(5):374-8. PubMed ID: 19826356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General and statistical hierarchy of appropriate biologic endpoints.
    Sargent D
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological assessment of tumour response to anti-cancer drugs: time to reappraise.
    Nygren P; Blomqvist L; Bergh J; Aström G
    Acta Oncol; 2008; 47(2):316-8. PubMed ID: 18210304
    [No Abstract]   [Full Text] [Related]  

  • 13. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.
    Mengelbier LH; Karlsson J; Lindgren D; Valind A; Lilljebjörn H; Jansson C; Bexell D; Braekeveldt N; Ameur A; Jonson T; Kultima HG; Isaksson A; Asmundsson J; Versteeg R; Rissler M; Fioretos T; Sandstedt B; Börjesson A; Backman T; Pal N; Øra I; Mayrhofer M; Gisselsson D
    Nat Commun; 2015 Jan; 6():6125. PubMed ID: 25625758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New scale assesses benefits of cancer medicines.
    Bagcchi S
    Lancet Oncol; 2015 Jul; 16(7):e316. PubMed ID: 26051234
    [No Abstract]   [Full Text] [Related]  

  • 16. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
    Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
    Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making sense of cancer chemotherapy.
    Holmes S
    Nurs Times; 1996 Sep 4-10; 92(36):42-3. PubMed ID: 8868768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic failure of antineoplastic agents. Extracellular and cellular causes].
    Hofsli E
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):37-40. PubMed ID: 2000585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.
    Devriese LA; Voest EE; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2011 Dec; 37(8):579-89. PubMed ID: 21592671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes.
    Sezer A; Sumbul AT; Abali H
    Asian Pac J Cancer Prev; 2014; 15(2):1061-2. PubMed ID: 24568451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.